Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06465108 · ClinicalTrials.gov registry record · Phase 2

Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism

A Phase 2 study of Hypoparathyroidism, sponsored by MBX Biosciences.

Completed
Registry status
Phase 2
Development phase
64
Enrollment target
20
Study locations

NCT06465108 is a Phase 2 study of Hypoparathyroidism that has completed, run by MBX Biosciences. The registered enrollment target is 64 participants, below the 193-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (67% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06465108, a Phase 2 study of Hypoparathyroidism, has completed, sponsored by MBX Biosciences.

COMPLETED
Registry status
Phase 2
Development phase
64 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to investigate the safety and tolerability of MBX 2109 administered once weekly to patients with hypoparathyroidism.

Conditions Studied

Hypoparathyroidism

Interventions

  • OTHER Placebo
  • DRUG MBX 2109

Study Locations (20)

New York

  • MBX Biosciences Investigational Site - Albany
  • MBX Biosciences Investigational Site - Great Neck
  • MBX Biosciences Investigational Site - New York
  • MBX Biosciences Investigational Site - The Bronx

Florida

  • MBX Biosciences Investigational Site - Jacksonville
  • MBX Biosciences Investigational Site - Jacksonville
  • MBX Biosciences Investigational Site - Miami

Illinois

  • MBX Biosciences Investigational Site - Chicago
  • MBX Biosciences Investigational Site - Chicago

Nevada

  • MBX Biosciences Investigational Site - Las Vegas
  • MBX Biosciences Investigational Site - Reno

Ohio

  • MBX Biosciences Investigational Site - Cleveland
  • MBX Biosciences Investigational Site - Columbus

California

  • MBX Biosciences Investigational Site - Sacramento

Georgia

  • MBX Biosciences Investigational Site - Macon

Mississippi

  • MBX Biosciences Investigational Site - Jackson

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2024-08-08
Est. Completion 2025-06-04
Phase Phase 2

Sponsor

MBX Biosciences

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06465108

The ClinicalTrials.gov registry entry for NCT06465108 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 193-participant average among 10 other Hypoparathyroidism trials with a reported enrollment target (67% lower). The listed sponsor is MBX Biosciences, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypoparathyroidism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT06465108 reports 20 study locations spanning 12 distinct geographic areas - top geographies include New York, Florida, Illinois.

Frequently Asked Questions

What is clinical trial NCT06465108 about?

NCT06465108 is a clinical study titled "Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism". The purpose of this study is to investigate the safety and tolerability of MBX 2109 administered once weekly to patients with hypoparathyroidism.

What is the current status of trial NCT06465108?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2024-08-08. Estimated completion is 2025-06-04.

What conditions does trial NCT06465108 study?

This clinical trial studies the following conditions: Hypoparathyroidism.

What interventions are being tested in trial NCT06465108?

The interventions under investigation include: Placebo (OTHER), MBX 2109 (DRUG).

Who is sponsoring clinical trial NCT06465108?

This trial is sponsored by MBX Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06465108 being conducted?

This trial has 20 study locations across California, Florida, Georgia, Illinois, Mississippi. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypoparathyroidism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypoparathyroidism

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.